KIT Gene Function
KIT Proto-Oncogene, Receptor Tyrosine Kinase
Overview
KIT is a receptor tyrosine kinase activated by stem-cell factor. Activating KIT mutations can drive gastrointestinal stromal tumours and some haematological or melanocytic cancers; the affected exon and protein domain influence biological and treatment interpretation.
Molecular Mechanism
Detailed mechanism data is not yet available for KIT.
Key Pathways
- ·Receptor tyrosine-kinase signalling
- ·RAS–MAPK signalling
- ·PI3K–AKT signalling
Disease Associations
- ·Gastrointestinal stromal tumour
- ·Systemic mastocytosis
- ·Core-binding-factor AML
- ·Melanoma
Research Activity
KIT is an actively studied target: about 700+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track KIT trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About KIT
What does KIT do?
KIT participates in Receptor tyrosine-kinase signalling, RAS–MAPK signalling, PI3K–AKT signalling. KIT is a receptor tyrosine kinase activated by stem-cell factor. Activating KIT mutations can drive gastrointestinal stromal tumours and some haematological or melanocytic cancers; the affected exon and protein domain influence biological and treatment interpretation.
Why is KIT relevant to cancer research?
Its reported relevance includes Gastrointestinal stromal tumour, Systemic mastocytosis, Core-binding-factor AML. The exact alteration, assay and disease context determine what a result can support.